Inhaled steroids in stable chronic obstructive pulmonary disease

steroids

1. Jakcevicius С.A., Chapman K.R. Prevalence of inhaled corticosteroid use among patients with chronic obstructive pulmonary disease: a survey. Ann Pharmacother 1997; 31: 160-164.

2. Roche N., Lepage T., Bourcereau J., Terriox P. Guidelines versus clinical practice in the treatment of chronic obstructive pulmonary disease. Eur. Respir. J. 2001; 18: 903-908.

3. Siafakas N.M., Vermeire P.. Pride N.B. et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur. Respir. J. 1995; 8: 1398-1420.

4. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. National Institutes of Health; National Heart, Lung and Blood Institute, update 2003.

5. Хроническая обструктивная болезнь легких (Федеральная программа). Практическое руководство для врачей. М.: 2004.

6. Celli B.R., MacNee W., and committee members. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS-position paper. Eur. Respir. J. 2004; 23: 932-946.

7. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004: 59 (suppl.): il-i232.

8. Iqbal A., Schloss S., George D. et al. Worldwide guidelines for chronic obstructive pulmonary disease: A comparison of diagnosis and treatment recommendations. Respirology 2002; 7: 233-239.

9. Caluerley P.M.A. Inhaled corticosteroids are beneficial in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2000: 161: 341-342.

10. Barnes P.J. Inhaled corticosteroids are not beneficial in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2000; 161: 342-343.

11. Nisar M., Walshaw M.J., Earis E. et al. Assessment of reversibility of airway obstruction in patients with chronic obstructive airways disease. Thorax 1990; 45; 190-194.

12. Davies L., Nisar M., Pearson M.G. et al. Oral corticosteroid trials in the management of stable chronic obstructive pulmonary disease. Quart. J. Med. 1999: 92: 395-400.

13. Chanez P., Vignola A. M., O'Shaugnessy T. et al. Corticosteroid reversibility in COPD is related to features of asthma. Am. J. Respir. Crit. Care Med. 1997; 155: 1529-1534.

14. Vestbo J., Sorensen T.P., Lange A. et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 1999; 353: 1819-1823.

15. Pauwels R.A., Lofdahl C.G., Laitinen L.A. et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N. Engl. J. Med. 1999; 340: 1948-1953.

16. The Lung Health Study Research Group, Altose M.D., Redline S. et al. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N. Engl. J. Med. 2000; 343: 1902-1909.

17. Burge P.S., Calverley P.M., Jones P.W. et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease. Br. Med. J. 2000; 320: 1297-1303.

18. Jarad N.A., Wedzicha J.A., Burge P.S. et al. An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. Respir. Med. 1999; 93: 161-168.

19. Davies L., Angus R.M., Calverley P.M.A. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomized controlled trial. Lancet 1999; 354: 456-460.

20. Jeffery P.K. Structural and inflammatory changes in COPD: a comparison with asthma. Thorax 1998; 53: 129-136.

21. Keatings V.M., Collins P.D., Scott D.M. et al. Differences in interleukin-8 and tumor necrosis factor- in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am. J. Respir. Crit. Care Med. 1996; 153: 530-534.

22. Barnes P.J., Pedersen S., Busse W.W. Efficacy and safety of inhaled corticosteroids: an update. Am. J. Respir. Crit. Care Med. 1998; 157: S1-S53.

23. Culpitt S.V., Nightingale J.A., Barnes P.J. Effect of fluticasone propionate on induced sputum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with COPD. Am. J. Respir. Crit. Care Med. 1999; 160: 1635-1639.

24. Keatings V.M., Jatakanon A.Y., Worsdel M. et al. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am. J. Respir. Crit. Care Med. 1997; 155: 542-548.

25. Gizycki M.J., Hattotuwa K.T., Barnes P.J. et al. Effects of flu-ticason propionate on inflammatory cells in COPD: an ultra-structural examination of endobronchial biopsy tissue. Thorax 2002; 57: 799-803.

26. Burge P.S. EUROSCOP, ISOLDE and the Copenhagen City Lung Study. Thorax 1999; 54: 287-288.

27. Nadel J.A. Role of mast cell and neutrophil proteases in airway secretion. Am. J. Respir. Care Med. 1991; 144: 548-551.

28. West bo J., Prescott E., Lange P. Association of chronic mucus hypersecretion with FEV| decline and chronic obstructive pulmonary disease morbidity. Am. J. Respir. Care Med. 1996; 153: 1530-1535.

29. Barnes P., Kazuhiro I., Adcock l.M. Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetilase. Lancet 2004; 363: 731-733.

30. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. Eur. Respir. J. 2004; 24: 206-210.